Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

VISIOPHARM A/S - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%   Bankruptcy risk   2.3% 2.3% 3.4% 3.0% 3.5% 3.1% 2.8% 2.8%   Credit score (0-100)   66 64 53 57 52 56 60 60   Credit rating   BBB BBB BBB BBB BBB BBB BBB BBB   Credit limit (mDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   88 84 108 136 112 118 118 118   Gross profit   33.7 44.5 66.9 84.2 86.8 90.2 0.0 0.0   EBITDA   -18.9 -20.2 -38.5 -19.1 -14.5 -2.4 0.0 0.0   EBIT   -23.3 -29.1 -46.2 -27.8 -24.1 -12.4 0.0 0.0   Pre-tax profit (PTP)   -23.7 -31.7 -46.7 -24.3 -29.2 -17.5 0.0 0.0   Net earnings   -21.7 -26.3 -41.3 -20.6 -30.9 -17.4 0.0 0.0   Pre-tax profit without non-rec. items   -23.7 -31.7 -46.7 -24.3 -29.2 -17.5 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   0.7 0.7 0.8 1.5 0.9 0.4 0.0 0.0   Shareholders equity total   77.1 100 59.4 33.6 24.5 9.2 8.7 8.7   Interest-bearing liabilities   1.8 1.9 3.3 16.0 34.1 33.9 9.3 9.3   Balance sheet total (assets)   115 154 134 108 129 118 18.0 18.0   Net Debt   -61.3 -89.0 -50.8 -19.6 -14.4 -13.4 9.3 9.3     See the entire balance sheet 1.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   88 84 108 136 112 118 118 118   Net sales growth   56.6% -4.2% 28.8% 25.3% -17.6% 5.4% 0.0% 0.0%   Gross profit   33.7 44.5 66.9 84.2 86.8 90.2 0.0 0.0   Gross profit growth   51.5% 32.3% 50.1% 25.9% 3.1% 3.9% -100.0% 0.0%   Employees   0 0 86 105 96 88 0 0   Employee growth %   0.0% 0.0% 0.0% 22.1% -8.6% -8.3% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   115 154 134 108 129 118 18 18   Balance sheet change%   -9.5% 33.5% -13.4% -19.4% 19.9% -8.2% -84.8% 0.0%   Added value   -18.9 -20.2 -38.5 -19.1 -15.3 -2.4 0.0 0.0   Added value %   -21.5% -24.0% -35.5% -14.0% -13.7% -2.0% 0.0% 0.0%   Investments   -1 -9 -7 -5 -9 -11 -0 0   Net sales trend   1.0 -1.0 1.0 2.0 -1.0 1.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   -21.5% -24.0% -35.5% -14.0% -12.9% -2.0% 0.0% 0.0%   EBIT %   -26.5% -34.5% -42.6% -20.4% -21.5% -10.5% 0.0% 0.0%   EBIT to gross profit (%)   -69.2% -65.3% -69.1% -33.0% -27.7% -13.7% 0.0% 0.0%   Net Earnings %   -24.7% -31.2% -38.1% -15.2% -27.6% -14.7% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -19.7% -20.6% -31.0% -8.7% -19.0% -6.2% 0.0% 0.0%   Pre tax profit less extraordinaries %   -27.0% -37.7% -43.1% -17.9% -26.0% -14.8% 0.0% 0.0%   ROA %   -18.8% -21.6% -31.7% -19.3% -19.8% -9.2% 0.0% 0.0%   ROI %   -24.0% -30.0% -51.5% -37.8% -37.5% -18.6% 0.0% 0.0%   ROE %   -24.6% -29.6% -51.7% -44.3% -106.4% -103.1% 0.0% 0.0%   1.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   67.4% 65.9% 45.0% 31.6% 19.2% 7.8% 48.4% 48.4%   Relative indebtedness %   43.6% 63.8% 68.3% 54.2% 93.2% 92.5% 7.9% 7.9%   Relative net indebtedness %   -28.1% -44.2% 18.5% 28.0% 49.9% 52.4% 7.9% 7.9%   Net int. bear. debt to EBITDA, %   323.3% 441.0% 132.1% 103.0% 99.5% 560.0% 0.0% 0.0%   Gearing %   2.3% 1.9% 5.5% 47.7% 138.8% 370.2% 106.6% 106.6%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   66.1% 142.8% 41.7% 10.3% 22.8% 18.0% 0.0% 0.0%   1.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   2.8 2.7 1.4 1.2 1.3 1.0 0.0 0.0   Current Ratio   2.7 2.6 1.4 1.2 1.4 1.0 0.0 0.0   Cash and cash equivalent   63.1 91.0 54.1 35.7 48.5 47.3 0.0 0.0   1.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   89.0 101.6 101.5 47.1 64.3 58.4 0.0 0.0   Trade creditors turnover (days)   82.3 54.4 77.0 10.4 77.0 85.2 0.0 0.0   Current assets / Net sales %   101.1% 141.9% 87.0% 46.0% 75.8% 63.3% 0.0% 0.0%   Net working capital   55.9 73.3 24.5 8.3 22.3 1.8 -4.6 -4.6   Net working capital %   63.6% 87.0% 22.6% 6.1% 19.9% 1.5% -3.9% -3.9%   1.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 1 1 1 1 0 0   Added value / employee   0 0 -0 -0 -0 -0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 -0 -0 -0 -0 0 0   EBIT / employee   0 0 -1 -0 -0 -0 0 0   Net earnings / employee   0 0 -0 -0 -0 -0 0 0